Bremelanotide Treatment Guide: Vyleesi, HSDD, and Provider Paths
In the United States, bremelanotide is approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Its on-demand dosing and central mechanism of action distinguish it from peripheral therapies.
This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.
Bremelanotide is a melanocortin-4 receptor agonist approved for HSDD in premenopausal women. Unlike phosphodiesterase inhibitors that work peripherally, bremelanotide acts centrally to modulate sexual desire and arousal pathways. It is dosed on demand rather than daily, which changes the adherence and cost structure compared to chronic medications.
Approved Product Paths
Branded bremelanotide for HSDD in premenopausal women. Dosed as 1.75 mg SC on demand before anticipated sexual activity. Maximum 1 dose per 24 hours and 8 doses per month.
- •FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women
- •On-demand dosing avoids daily medication burden and allows situational use
- •Central mechanism targets desire pathways rather than peripheral blood flow
- •A regulated pathway that can be paired with provider matching and cost review
- •Nausea is the most common side effect, occurring in approximately 40% of patients
- •Transient blood pressure increases and flushing require monitoring
- •Skin hyperpigmentation may develop with repeated use, especially in darker skin tones
- •Contraindicated in patients with uncontrolled hypertension or cardiovascular disease
How Bremelanotide Works
Bremelanotide is a synthetic heptapeptide melanocortin receptor agonist. It activates melanocortin-4 receptors (MC4R) in the central nervous system to increase sexual desire and arousal in premenopausal women with hypoactive sexual desire disorder (HSDD).
Bremelanotide is a cyclic 7-amino-acid peptide analog of alpha-melanocyte stimulating hormone (α-MSH). It crosses the blood-brain barrier and binds to MC4R receptors in hypothalamic and limbic circuits involved in sexual motivation and reward.
MC4R activation in the medial preoptic area and ventromedial hypothalamus modulates dopaminergic and oxytocinergic pathways that govern sexual desire. This is distinct from peripheral vasodilator mechanisms (PDE5 inhibitors work on blood flow; bremelanotide works on central desire).
The drug also has activity at MC1R (melanocortin-1 receptor), which explains its side effect of hyperpigmentation and tanning. This MC1R effect is dose-dependent and more pronounced with chronic use.
Bremelanotide is administered as needed (not daily) via subcutaneous injection, typically 45 minutes before anticipated sexual activity. This on-demand mechanism matches the intermittent nature of sexual activity better than daily oral medications.
Unlike flibanserin (the other FDA-approved HSDD treatment), bremelanotide does not interact with serotonin receptors and carries no alcohol interaction warning. It also works within minutes to hours rather than weeks.
The central mechanism means bremelanotide increases desire and arousal but does not directly affect genital blood flow. For women with arousal disorders secondary to vascular issues, PDE5 inhibitors or local therapies may be more appropriate.
Clinical Trial Evidence
RECONNECT trials (two identical phase 3 studies)
- FSFI-D score improved 0.3 vs 0.1 placebo (p<0.01)
- FSDS-R distress score improved -7.5 vs -5.6 placebo (p<0.01)
- Sexually satisfying events increased modestly
- Effect size is small but statistically significant and clinically meaningful to some patients
Dosing & Administration
- •Inject subcutaneously into thigh or abdomen
- •Administer 45 minutes before anticipated sexual activity
- •Do not use more than once per 24 hours
- •Do not exceed 8 doses per month
- •May self-administer after training
Side Effect Profile
Very common
Most common side effect; usually transient lasting 1-2 hours
Warmth and redness of face/neck/chest
Erythema, pain, bruising
Transient
Cardiovascular
Transient increase of 2-6 mmHg systolic; contraindicated in uncontrolled hypertension
Dermatologic
Darkening of skin, especially face and gums; may not fully reverse after discontinuation
Contraindications & Warnings
Do Not Use
- Uncontrolled hypertension
- Known cardiovascular disease (relative contraindication; discuss risks)
- Severe hepatic or renal impairment
- Pregnancy or breastfeeding
- Known hypersensitivity to bremelanotide
Important Warnings
- Transient blood pressure elevation lasting 2-4 hours after injection; avoid in patients with cardiovascular risk
- Nausea is very common (40%) and may limit tolerability
- Hyperpigmentation risk increases with cumulative doses; may be permanent
- No alcohol interaction (unlike flibanserin), but alcohol may worsen nausea
- Not for postmenopausal women (not studied; not approved)
Drug Interactions
| Drug | Interaction | Severity | Mechanism |
|---|---|---|---|
| Naltrexone | May reduce efficacy | moderate | Opioid antagonists may interfere with melanocortin system reward pathways |
| Antihypertensives | May mask BP elevation | minor | Patients on BP meds may not detect transient BP rise |
| Alcohol | None significant | minor | No pharmacokinetic interaction; alcohol may worsen nausea |
Monitoring Requirements
- Blood pressure before starting and periodically
- Skin examination for hyperpigmentation with cumulative use
- Assessment of sexual desire and distress scores at follow-up
- Nausea tolerance and adherence
How Bremelanotide Compares
Different mechanisms; some patients respond to one but not the other
Bremelanotide works immediately; flibanserin requires chronic dosing
Major practical advantage for social drinkers
Different side effects; patient preference varies
Daily oral is easier for many than as-needed injection
Bremelanotide has specific indication; testosterone use in women is off-label
Evidence Quality Assessment
Is Bremelanotide Right for You?
Ideal Candidates
- Premenopausal women with acquired, generalized HSDD
- Patients who prefer as-needed rather than daily therapy
- Women who consume alcohol socially (no alcohol restriction)
- Those who failed or cannot tolerate flibanserin
- Patients with intact cardiovascular status and normal blood pressure
Avoid
- Postmenopausal women (not approved, not studied)
- Uncontrolled hypertension or significant cardiovascular disease
- Patients with severe nausea sensitivity
- Pregnancy or breastfeeding
- Patients unwilling to self-inject
Use With Caution
- Controlled hypertension
- History of nausea or GI disorders
- Patients on opioid antagonists
- Dark skin types (may notice hyperpigmentation more readily)
Cost & Insurance Deep Dive
Savings Programs
Cost-Effectiveness Notes
- •High cost per sexually satisfying event gained
- •As-needed dosing means cost scales with frequency of use
- •Many patients try 1-2 doses and discontinue due to nausea or modest benefit
- •Cost-effectiveness is controversial given small effect size
Ready to find a bremelanotide provider?
Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.
Find a bremelanotide providerWellness Support Products
Tools and supplements that support overall health and vitality.
Smart WiFi Body Scale
Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.
Digital Kitchen Food Scale
Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.
Protein Shaker Bottle Set
Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Recommended Reading
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Bremelanotide FAQ
Sources
- 1. Vyleesi (bremelanotide) for HSDDPalatin Technologies • 2026Claim type: clinicalView source →
- 2. Effect of Bremelanotide on Sexual Desire in WomenJAMA Internal Medicine • 2019Claim type: clinicalView source →
- 3. FDA approves Vyleesi for hypoactive sexual desire disorderFDA • 2019Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.